Novartis accelerates full-chain innovation ecosystem in China
Novartis has greatly enhanced the availability of innovative cancer treatments for Chinese patients. Through its comprehensive full-chain strategy in China, the company makes global breakthrough therapies accessible to Chinese patients with no delay compared to international markets.

Novartis in Pudong New Area. [Photo/WeChat ID: pdnews]
At the 8th China International Import Expo (CIIE) on Nov 5, Novartis introduced Pluvicto, China's first radioligand therapy (RLT) approved for two indications.
Novartis has invested more than 600 million yuan ($84.41 million) to build China's first RLT manufacturing facility. Expected to start operations by the end of 2026, this plant will adhere to global standards, aiming to shorten transportation times and enhance supply reliability.
Since its debut at the CIIE in 2018, Novartis has had over 40 innovative drugs approved in China. The introduction of Pluvicto at this year's CIIE makes it the first PSMA-targeted RLT for advanced prostate cancer, providing new treatment options for patients.
Novartis is committed to speeding up drug development in China, with over 100 clinical trials currently in progress. The company plans to have 90 percent of its new drug and indication approvals in China synchronized with global approvals within the next two years.
The integration of RLT into China's healthcare system is about more than just products; it also involves creating a collaborative ecosystem with key partners, including Siemens Healthineers, to standardize diagnostic and treatment pathways. Novartis is also investigating new payment models to enhance patient access to these high-value therapies.
Contact Us

Pudong lights up city with spectacular shows and cultural marvels
Brilliant light show to illuminate Huangpu River
Maple leaves paint splendid scenery in Pudong
Appreciate alluring lotus blossoms in Pudong's Century Park